Rectal Cancer Clinical Trial
Official title:
Robotic-assisted Versus Conventional Laparoscopic Approach for Rectal Cancer Surgery, First Egyptian Academic Center Experience, Randomized Controlled Trial (RCT)
This is a prospective randomized controlled study that was conducted on patients of both sexes and definite age group at National Cancer Institute-Egypt and with adenocarcinoma of the rectum located within 15 cm from the anal verge. Tumor localization was categorized as the upper rectum (distal border of tumor is from 10 to 15 cm from the anal verge), middle rectum (5 to 10 cm from the anal verge) or lower rectum (less than 5 cm from the anal verge) as measured by colonoscopy and digital rectal examination. Patients were classified into two groups; robotic assisted rectal surgery and conventional laparoscopic rectal surgery.Baseline demographics (gender, age, ASA, BMI), preoperative data (distance of the tumor from the anal verge, clinical stage, whether preoperative chemoradiation (CRT), presence of residual tumor after CRT, intraoperative data (preparation time, actual operative time, estimated blood loss, conversion rate to open surgery), postoperative data (pathological stage, number of harvested lymph nodes, macroscopic completeness of resection in the form of proximal margin, distal margin, circumferential radial margin) and immediate postoperative outcome within one month (days of return of bowel function, days of hospital stay, complications, if any, like anastomotic leakage, ileus,wound problems and others, rate of re-operation, rate of readmission & 30-days mortality) were analyzed and compared.The criteria for patients selection were the following: histological diagnosis of adenocarcinoma of rectum, no anesthesiological contraindications to minimally invasive surgery, age ≤ 75 years, American Society of Anesthesiologists (ASA) ≤ 2 & the procedures performed by the same surgical team. Patients with metastatic disease, malignant bowel obstruction and those with irresectable tumor were excluded from our study.Preoperative workup (endoscopy with biopsies, radiological imaging including pelvic MRI, liver ultrasound, chest X-ray and routine abdominal and digital rectal examinations) was routinely carried out. The assignment of patients to either group was done by a permuted block randomization. It was an open-labeled study. The study was approved by the institutional review board of National Cancer Institute-Cairo University. All patients provided written informed consent.
Undoubtedly, robotic systems have largely penetrated the surgical field.For any new operative
approach to become an accepted alternative to conventional methods, it must be proved safe
and result in comparable outcomes. The purpose of this study is to compare the short-term
operative as well as oncologic outcomes of robotic assisted and laparoscopic rectal cancer
resection.
This is a prospective randomized controlled study that was conducted on all patients of both
sexes and definite age group attending the National Cancer Institute and with adenocarcinoma
of the rectum located within 15 cm from the anal verge who were eligible to be included in
the study. Tumor localization was categorized as the upper rectum (distal border of tumor is
from 10 to 15 cm from the anal verge), middle rectum (5 to 10 cm from the anal verge) or
lower rectum (less than 5 cm from the anal verge) as measured by colonoscopy and digital
rectal examination. Patients were classified into two groups; robotic assisted rectal surgery
"The robotic system that we use is the da Vinci Si(Intuitive Surgical, Inc.,Sunnyvale,CA)"
and conventional laparoscopic rectal surgery. Baseline demographics (gender, age, ASA, BMI),
preoperative data (distance of the tumor from the anal verge, clinical stage, whether
preoperative chemo-radiation "CRT", presence of residual tumor after CRT), intraoperative
data (preparation time, actual operative time, estimated blood loss, conversion rate to open
surgery), postoperative data (pathological stage, number of harvested lymph nodes,
macroscopic completeness of resection in the form of proximal margin, distal margin,
circumferential radial margin) and immediate postoperative outcome within one month (days of
return of bowel function, days of hospital stay, complications, if any, like anastomotic
leakage, ileus, wound problems and others, rate of reoperation, rate of readmission & 30-days
mortality) were analyzed and compared.The criteria for patients selection were the following:
histological diagnosis of adenocarcinoma of rectum, no anesthesiological contraindications to
minimally invasive surgery, age ≤ 75 years, ASA ≤ 2 & the procedures performed by the same
surgical team. Patients with metastatic disease, malignant bowel obstruction (MBO) and those
with irresectable tumor were excluded from our study. Preoperative workup (endoscopy with
biopsies, radiological imaging including pelvic MRI, liver ultrasound, chest X-ray and
routine abdominal and digital rectal examinations) was routinely carried out. The assignment
of patients to either group was done by a permuted block randomization. It was an
open-labeled study i.e. patients, investigators (surgeons, researchers) and data collectors
knew which procedure will be done to which patients. The study was approved by the
institutional review board of the National Cancer Institute, Cairo University. All patients
provided written informed consent.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |